 | | Vol. 6.03 – 28 January, 2022 |
| |
|
|
| Researchers identified a novel role of Copper (Cu) in promoting radioresistance of HCC cells. Ionizing radiation induced a reduction of copper metabolism MURR1 domain 10 (COMMD10), which increased intracellular Cu and led to radioresistance of HCC.
[Journal of Hepatology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors reported that hepatitis C virus (HCV) infection was favored by heparanase-1 (HPSE), and upregulated HPSE expression and secretion, which may have resulted in potentially pathogenic alterations of the extracellular matrix.
[Journal of Hepatology] |
|
|
|
| The therapeutic efficacy and the molecular pathways targeted by TVB3664, either alone or with tyrosine kinase inhibitors or the checkpoint inhibitor anti-PD-L1 antibody, were assessed in human HCC cell lines and multiple oncogene-driven HCC mouse models.
[Hepatology] |
|
|
|
| Investigators performed whole-genome sequencing on 40 pairs of primary and early-recurrent hepatitis B virus (HBV)-related HCC tumors from patients who received curative resection, and from four patients whose primary and recurrent tumors were extensively sampled.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Scientists showed in HCC cells, xenografts, and patient-derived organoids that fasting improved sorafenib efficacy and acted synergistically to sensitize sorafenib-resistant HCC.
[Science Advances] |
|
|
|
| The authors showed that mitochondrial MATα1 was selectively depleted in alcohol-associated liver disease through a mechanism that involved the isomerase PIN1 and the kinase CK2.
[Nature Communications] |
|
|
|
| Researchers investigated the molecular mechanism underlying galectin-1-mediated chemoresistance in HCC cells, particularly the involvement of P-glycoprotein in this effect.
[Cell Death & Disease] |
|
|
|
| The authors established a novel miRNA signature that could robustly predict survival outcomes in resected tissues and liquid biopsies to improve the clinical management of patients with intrahepatic cholangiocarcinoma.
[British Journal of Cancer] |
|
|
|
| Scientists showed that the expression of discoid protein domain receptor 1 was significantly increased in HCC and was related to a poor clinical prognosis.
[Cellular Oncology] |
|
|
|
| Investigators indicated that TEAD2/4 were significantly upregulated in HCC compared with normal tissues. Downregulation of TEAD2 promoted the death of HCC cells through inducing ferroptosis by iron accumulation and subsequent oxidative damage.
[Aging] |
|
|
|
| Researchers found that the acidic tumor microenvironment contributed to lipid accumulation in liver cancer by activating the PI3K/AKT signaling pathway and promoting SCD1-PPARα binding.
[Molecular Cancer Research] |
|
|
|
| Scientists explored the role of corticotropin releasing hormone binding protein (CRHBP) in HCC development, and whether p62-mediated autophagy was responsible for low CRHBP expression within HCC tissue.
[Cancer Gene Therapy] |
|
|
|
| Investigators evaluated the effects of chimeric Ab27 using cancer cells expressing endogenous transmembrane 4 L six family member 5 (TM4SF5) or stably overexpressing TM4SF5 in vivo and in vitro.
[Molecular Therapy-Oncolytics] |
|
|
|
|
| The authors summarize the diverse roles of Hippo signaling in liver biology and highlight areas where outstanding questions remain to be investigated.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Scientists describe the potential for chronopharmacology in non-alcoholic steatohepatitis (NASH), discuss how the major NASH drug candidates are influenced by circadian biology, and encourage greater consideration of the timing of drug administration in the design of future clinical trials.
[Journal of Hepatology] |
|
|
|
| Investigators summarize the regulating mechanisms of autophagy through different targets and signal pathways in energy metabolism-related hepatic fibrosis and discuss the regulatory effect of autophagy by natural plant-derived, endogenous and synthetic compounds for the treatment of hepatic fibrosis.
[Pharmacology & Therapeutics] |
|
|
|
|
| 89bio, Inc. announced positive topline results from an open-label expansion cohort of 20 patients in the Phase Ib/IIa proof-of-concept study evaluating pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).
[89bio, Inc.] |
|
|
|
| Aligos Therapeutics, Inc. announced that the first chronic hepatitis B patient has been dosed in the multiple ascending dose portion of study ALG-020572-401 which is evaluating antisense oligonucleotide ALG-020572.
[Aligos Therapeutics, Inc.] |
|
|
|
|
| February 10 – 12, 2022
Lorne, Victoria, Australia |
|
|
|
|
|
| | University of Vermont – Burlington, Vermont, United States |
|
|
|
| | University of Texas Medical Branch – Galveston, Texas, United States |
|
|
|
| | Center for Cooperative Research in Biosciences – Derio, Spain |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | NIH National Institute on Alcohol Abuse and Alcoholism – Bethesda, Maryland, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
